No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ANIP240517P65000
- 2.60
- +2.25+642.86%
15min DelayTrading May 17 11:30 ET
2.60High2.60Low
2.60Open0.35Pre Close1 Volume59 Open Interest65.00Strike Price260.00Turnover0.00%IV0.42%PremiumMay 17, 2024Expiry Date2.81Intrinsic Value100Multiplier0DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma24.39Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Insider Selling: President & CEO Nikhil Lalwani Sells Shares of ANI Pharmaceuticals Inc (ANIP)
ANI Pharmaceuticals(ANIP.US) Officer Sells US$1.1 Million in Common Stock
$ANI Pharmaceuticals(ANIP.US)$ Officer Lalwani Nikhil sold 16,669 shares of common stock on May 14, 2024 at an average price of $66.1 for a total value of $1.1 million.Source: Announcement What is sta
Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing
Nikhil Lalwani, Director, President & CEO, on May 14, 2024, sold 16,669 shares in Ani Pharmaceuticals (ANIP) for $1,101,821. Following the Form 4 filing with the SEC, Lalwani has control over a total
Form 144 | ANI Pharmaceuticals(ANIP.US) Insider Proposes to Sell 127.73K in Common Stocks
SEC FILLINGS DISCLOSED/ May 16, $ANI Pharmaceuticals(ANIP.US)$ Insider RENATE TANNENBAUM intends to sell 2,000 shares of its common stock on May 16, with a total market value of approximately $127.73K
Form 144 | ANI Pharmaceuticals(ANIP.US) Officer Proposes to Sell 1.05 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 16, $ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy intends to sell 16,459 shares of its common stock on May 16, with a total market value of approximately $1.05
Form 144 | ANI Pharmaceuticals(ANIP.US) Officer Proposes to Sell 978K in Common Stocks
SEC FILLINGS DISCLOSED/ May 15, $ANI Pharmaceuticals(ANIP.US)$ Officer Shanmugam Muthusamy intends to sell 14,850 shares of its common stock on May 15, with a total market value of approximately $978K
Comments
Despite last quarter's price drop, ANI Pharmaceuticals, Inc. is seen promising due to strong share price momentum. The firm's shift from loss to profitability in the past three years signals good performance and growth.
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Shareholders Respectable 19% CAGR Over 3 Years, Surging 5.9% in the Last Week AloneThe company's weak ROE, falling net income, and retention of most profits without sufficient growth may not benefit investors. Future earnings, though, are projected to grow.
Gainers:
• $La-Z-Boy(LZB.US$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer(PFE.US$)
• $Ikena Oncology(IKNA.US$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
• $La-Z-Boy(LZB.US$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US$ +6.7% (ENTA files patent infringement lawsuit against $Pfizer(PFE.US$)
• $Ikena Oncology(IKNA.US$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
8
1
Read more